PP 2 (AG 1879): From Src Biology to Translation
2026-08-21
PP 2 (AG 1879) offers a practical way to interrogate Src family kinase signaling across oncology, immunology, and vascular biology. This thought-leadership guide connects its biochemical selectivity with evidence from glioma, T-cell, and ROS-driven arterial models while defining the controls needed for translationally credible experiments.
Ranolazine: From Ion Flux to Translational Strategy
2026-08-20
A mechanism-led perspective on using Ranolazine to connect late sodium current inhibition, myocardial relaxation, metabolic efficiency, and carefully bounded liver-cell research.
Osteoblast ECM1 and Anti-Androgen Resistance
2026-08-20
The reference study identifies osteoblast-derived ECM1 as a microenvironmental driver of enzalutamide resistance in bone metastatic prostate cancer. It maps an ECM1–ENO1–GRB2/SOS1–MAPK axis and shows that blocking ECM1 or ENO1 can restore treatment sensitivity, providing a rationale for targeting tumor–bone interactions in bmCRPC.
Antiarrhythmic Drugs and KCa2 Channels in AF
2026-08-19
The reference study systematically tested commonly used antiarrhythmic drugs against human KCa2.2 and KCa2.3 channels using automated whole-cell patch clamp. Its results show that dofetilide and propafenone inhibit these channels, whereas the observed potency is generally too low to explain their clinical antiarrhythmic effects, refining how KCa2 channels should be considered in atrial fibrillation treatment research.
Streptavidin – Cy5 for Translational Oncology
2026-08-19
A thought-leadership guide connecting USP42–JNK/p38 apoptosis biology with strategic assay design using Streptavidin – Cy5 for tissue imaging, immunofluorescence, in situ hybridization, and flow cytometry.
Dutasteride: Designing Mechanism-First Assays
2026-08-18
Dutasteride is a dual 5-alpha-reductase inhibitor suited to layered studies of DHT biology, prostate cancer research, and apoptosis. This article shows how an immunometabolic liver-injury study can sharpen assay design without overstating cross-domain evidence.
ACE2, Diminazene Aceturate, and Septic Cardiomyopathy
2026-08-18
The reference study identifies ACE2 downregulation as a feature of sepsis-induced cardiomyopathy and shows that pharmacological ACE2 activation with diminazene aceturate protects septic mice. Its central contribution is the proposed MasR-Sirt1 pathway, which connects ACE2 signaling with mitochondrial biogenesis, cardiac function, inflammation, oxidative stress, and apoptosis.
HIF-1–tiR-Lys Protects Renal Cells From Ferroptosis
2026-08-17
Li and colleagues identify tiRNA-Lys-CTT-003 as a downstream effector of HIF-1α that protects renal tubular cells from cisplatin-associated ferroptosis. Their evidence connects tiR-Lys to the RNA-binding protein GRSF1 and GPX4, providing a post-transcriptional explanation for how HIF activation limits oxidative tubular injury in acute kidney injury.
Phosphatase Inhibitor Cocktail 2 Workflow Guide
2026-08-17
Protect phosphorylation-dependent signaling readouts in liver, cell, and tissue lysates with a practical 100X workflow. This guide connects phosphoprotein preservation to the CerS6–C16:0 ceramide stress model and shows how to optimize Western blotting, immunoprecipitation, mitochondrial studies, and related assays.
Tin Mesoporphyrin IX: Translational HO Control
2026-08-16
A mechanistic and strategic guide to using Tin Mesoporphyrin IX (chloride) as a research tool for heme oxygenase inhibition, metabolic disease research, insulin resistance study design, and hypothesis-driven antiviral investigation.
Chloramphenicol for Plasmid Selection Workflows
2026-08-15
Chloramphenicol enables controlled plasmid selection, marker maintenance, and resistance-plasmid tracking without confusing selectable genotype with clinical phenotype. This workflow-focused guide connects a bacterial protein synthesis inhibitor with recent evidence on plasmid-borne carbapenemase transmission and shows how to improve assay reliability.
Talabostat Mesylate: Enzyme-to-Phenotype Assays
2026-08-15
Talabostat mesylate (PT-100) enables mechanistic studies of DPP4 and FAP inhibition from substrate cleavage to immune and tissue phenotypes. This article presents a phenotype-first assay strategy and explains how recent epidermal homeostasis research can sharpen experimental interpretation without implying an unproven NLRP10 interaction.
Ziprasidone HCl: Permeability and Cancer Workflows
2026-08-14
Build reproducible Caco-2 permeability, cancer-cell, and receptor-pathway experiments around Ziprasidone HCl. This guide connects formulation-aware handling with GOT1-focused oncology assays while distinguishing evidence from practical optimization.
Ajugol, Mitophagy, and Pyroptosis in Gout
2026-08-14
The reference study identifies PI3K/AKT/mTOR suppression as the mechanistic link between ajugol treatment, restored PINK1/Parkin-dependent mitophagy, and reduced chondrocyte pyroptosis in acute gouty arthritis. Its combined computational, cellular, and animal strategy supports mitochondrial quality control as a potential way to limit MSU-driven cartilage inflammation, while also highlighting the need for careful pathway-specific validation.
Pentoxifylline and Preterm Monocyte Hyperinflammation
2026-08-13
Schüller et al. developed an age-comparative in vitro model showing that pentoxifylline suppresses LPS-driven monocyte activation in preterm and term infants as well as adults. The study links reduced inflammatory cytokine production to lower cellular and transcriptional TLR4 activity, while also identifying age-dependent effects on surface markers, IL-10 production, and phagocytosis.
464 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page